Literature DB >> 33315178

Automated quantification of baseline imaging PET metrics on FDG PET/CT images of pediatric Hodgkin lymphoma patients.

Amy J Weisman1, Jihyun Kim2, Inki Lee3, Kathleen M McCarten4, Sandy Kessel4, Cindy L Schwartz5, Kara M Kelly6, Robert Jeraj1, Steve Y Cho2,7, Tyler J Bradshaw8.   

Abstract

PURPOSE: For pediatric lymphoma, quantitative FDG PET/CT imaging features such as metabolic tumor volume (MTV) are important for prognosis and risk stratification strategies. However, feature extraction is difficult and time-consuming in cases of high disease burden. The purpose of this study was to fully automate the measurement of PET imaging features in PET/CT images of pediatric lymphoma.
METHODS: 18F-FDG PET/CT baseline images of 100 pediatric Hodgkin lymphoma patients were retrospectively analyzed. Two nuclear medicine physicians identified and segmented FDG avid disease using PET thresholding methods. Both PET and CT images were used as inputs to a three-dimensional patch-based, multi-resolution pathway convolutional neural network architecture, DeepMedic. The model was trained to replicate physician segmentations using an ensemble of three networks trained with 5-fold cross-validation. The maximum SUV (SUVmax), MTV, total lesion glycolysis (TLG), surface-area-to-volume ratio (SA/MTV), and a measure of disease spread (Dmaxpatient) were extracted from the model output. Pearson's correlation coefficient and relative percent differences were calculated between automated and physician-extracted features.
RESULTS: Median Dice similarity coefficient of patient contours between automated and physician contours was 0.86 (IQR 0.78-0.91). Automated SUVmax values matched exactly the physician determined values in 81/100 cases, with Pearson's correlation coefficient (R) of 0.95. Automated MTV was strongly correlated with physician MTV (R = 0.88), though it was slightly underestimated with a median (IQR) relative difference of - 4.3% (- 10.0-5.7%). Agreement of TLG was excellent (R = 0.94), with median (IQR) relative difference of - 0.4% (- 5.2-7.0%). Median relative percent differences were 6.8% (R = 0.91; IQR 1.6-4.3%) for SA/MTV, and 4.5% (R = 0.51; IQR - 7.5-40.9%) for Dmaxpatient, which was the most difficult feature to quantify automatically.
CONCLUSIONS: An automated method using an ensemble of multi-resolution pathway 3D CNNs was able to quantify PET imaging features of lymphoma on baseline FDG PET/CT images with excellent agreement to reference physician PET segmentation. Automated methods with faster throughput for PET quantitation, such as MTV and TLG, show promise in more accessible clinical and research applications.

Entities:  

Keywords:  Convolutional neural networks; Imaging biomarkers; PET; Pediatric lymphoma

Year:  2020        PMID: 33315178     DOI: 10.1186/s40658-020-00346-3

Source DB:  PubMed          Journal:  EJNMMI Phys        ISSN: 2197-7364


  16 in total

1.  Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group.

Authors:  Kara M Kelly; Peter D Cole; Qinglin Pei; Rizvan Bush; Kenneth B Roberts; David C Hodgson; Kathleen M McCarten; Steve Y Cho; Cindy Schwartz
Journal:  Br J Haematol       Date:  2019-06-10       Impact factor: 6.998

2.  Pediatric lymphoma: metabolic tumor burden as a quantitative index for treatment response evaluation.

Authors:  Punit Sharma; Arun Gupta; Chetan Patel; Sameer Bakhshi; Arun Malhotra; Rakesh Kumar
Journal:  Ann Nucl Med       Date:  2011-10-28       Impact factor: 2.668

3.  Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial.

Authors:  Anne-Ségolène Cottereau; Annibale Versari; Annika Loft; Olivier Casasnovas; Monica Bellei; Romain Ricci; Stéphane Bardet; Antonio Castagnoli; Pauline Brice; John Raemaekers; Bénédicte Deau; Catherine Fortpied; Tiana Raveloarivahy; Emelie Van Zele; Loic Chartier; Thierry Vander Borght; Massimo Federico; Martin Hutchings; Umberto Ricardi; Marc Andre; Michel Meignan
Journal:  Blood       Date:  2018-02-01       Impact factor: 22.113

4.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Authors:  Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

5.  Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.

Authors:  Alison J Moskowitz; Heiko Schöder; Somali Gavane; Katie L Thoren; Martin Fleisher; Joachim Yahalom; Susan J McCall; Briana R Cadzin; Stephanie Y Fox; John Gerecitano; Ravinder Grewal; Paul A Hamlin; Steven M Horwitz; Anita Kumar; Matthew Matasar; Andy Ni; Ariela Noy; M Lia Palomba; Miguel-Angel Perales; Carol S Portlock; Craig Sauter; David Straus; Anas Younes; Andrew D Zelenetz; Craig H Moskowitz
Journal:  Blood       Date:  2017-09-05       Impact factor: 22.113

6.  Role of PET/CT in malignant pediatric lymphoma.

Authors:  Raef Riad; Walid Omar; Magdy Kotb; Magdy Hafez; Iman Sidhom; Manal Zamzam; Iman Zaky; Hussein Abdel-Dayem
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-15       Impact factor: 9.236

7.  A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425.

Authors:  Cindy L Schwartz; Louis S Constine; Doojduen Villaluna; Wendy B London; Robert E Hutchison; Richard Sposto; Steven E Lipshultz; Charles S Turner; Pedro A deAlarcon; Allen Chauvenet
Journal:  Blood       Date:  2009-07-07       Impact factor: 22.113

8.  Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's disease.

Authors:  Diane Tseng; Leelanand P Rachakonda; Zheng Su; Ranjana Advani; Sandra Horning; Richard T Hoppe; Andrew Quon; Edward E Graves; Billy W Loo; Phuoc T Tran
Journal:  Radiat Oncol       Date:  2012-01-19       Impact factor: 3.481

9.  Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation.

Authors:  Mani Akhtari; Sarah A Milgrom; Chelsea C Pinnix; Jay P Reddy; Wenli Dong; Grace L Smith; Osama Mawlawi; Zeinab Abou Yehia; Jillian Gunther; Eleanor M Osborne; Therese Y Andraos; Christine F Wogan; Eric Rohren; Naveen Garg; Hubert Chuang; Joseph D Khoury; Yasuhiro Oki; Michelle Fanale; Bouthaina S Dabaja
Journal:  Blood       Date:  2017-10-16       Impact factor: 25.476

10.  Pretherapeutic FDG-PET total metabolic tumor volume predicts response to induction therapy in pediatric Hodgkin's lymphoma.

Authors:  Julian M M Rogasch; Patrick Hundsdoerfer; Frank Hofheinz; Florian Wedel; Imke Schatka; Holger Amthauer; Christian Furth
Journal:  BMC Cancer       Date:  2018-05-03       Impact factor: 4.430

View more
  3 in total

Review 1.  Artificial Intelligence in Lymphoma PET Imaging:: A Scoping Review (Current Trends and Future Directions).

Authors:  Navid Hasani; Sriram S Paravastu; Faraz Farhadi; Fereshteh Yousefirizi; Michael A Morris; Arman Rahmim; Mark Roschewski; Ronald M Summers; Babak Saboury
Journal:  PET Clin       Date:  2022-01

Review 2.  Artificial Intelligence in Medical Imaging and its Impact on the Rare Disease Community: Threats, Challenges and Opportunities.

Authors:  Navid Hasani; Faraz Farhadi; Michael A Morris; Moozhan Nikpanah; Arman Rhamim; Yanji Xu; Anne Pariser; Michael T Collins; Ronald M Summers; Elizabeth Jones; Eliot Siegel; Babak Saboury
Journal:  PET Clin       Date:  2022-01

3.  Translational Applications of Artificial Intelligence and Machine Learning for Diagnostic Pathology in Lymphoid Neoplasms: A Comprehensive and Evolutive Analysis.

Authors:  Julia Moran-Sanchez; Antonio Santisteban-Espejo; Miguel Angel Martin-Piedra; Jose Perez-Requena; Marcial Garcia-Rojo
Journal:  Biomolecules       Date:  2021-05-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.